Drugs / Dimethandrolone Undecanoate
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02927210 | Feb 2017 → Nov 2024 | — | Kimberly Myer | Completed | No outcome recorded |
| Phase 1 | NCT01382069 | Mar 2012 → Feb 2017 | — | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03455075 | Apr 2018 → Mar 2020 | — | Premier Research | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dimethandrolone Undecanoate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01382069 ↗ |
| Known as | DMAU | “Dimethandrolone undecanoate (DMAU) is being developed as a male contraceptive.” PMID 33090208 ↗ Jan 2021 |
| Route | Oral | “Daily oral administration of DMAU for 28 days in healthy men is well tolerated.” PMID 30252061 ↗ Feb 2019 |